SOHM, Inc., Announce Dr. Tetsuya Kawamura Ph. D. Joined as a Cell Engineer and Biochemist
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced the appointment of Dr. Tetsuya Kawamura, Ph.D., as a Senior Cell Engineer and Biochemist. Dr. Kawamura brings extensive experience in biochemistry, molecular biology, and cellular biology. He has a proven track record in developing new methods for cell model creation, protein expression, and DNA/RNA production. Notably, Dr. Kawamura has authored patents in gene editing technology, including SOHM's ABBIE technology.
Dr. Kawamura's appointment is expected to enhance SOHM's scientific capabilities and support the advancement and commercialization of their ABBIE gene editing technology. The company anticipates that his expertise will aid in the timely release of ABBIE kits, as previously announced for the current quarter.
SOHM, Inc. (OTC PINK:SHMN), un'azienda farmaceutica e biotecnologica, ha annunciato la nomina del Dr. Tetsuya Kawamura, Ph.D., come Senior Cell Engineer e Biochimico. Il Dr. Kawamura porta con sé una vasta esperienza in biochimica, biologia molecolare e biologia cellulare. Ha una comprovata esperienza nello sviluppo di nuovi metodi per la creazione di modelli cellulari, espressione proteica e produzione di DNA/RNA. In particolare, il Dr. Kawamura ha autorizzato brevetti nella tecnologia di editing genetico, inclusa la tecnologia ABBIE di SOHM.
Si prevede che la nomina del Dr. Kawamura migliori le capacità scientifiche di SOHM e supporti l'avanzamento e la commercializzazione della loro tecnologia di editing genetico ABBIE. L'azienda si aspetta che la sua esperienza contribuirà al rilascio tempestivo dei kit ABBIE, come annunciato in precedenza per il trimestre in corso.
SOHM, Inc. (OTC PINK:SHMN), una compañía farmacéutica y biotecnológica, ha anunciado el nombramiento del Dr. Tetsuya Kawamura, Ph.D., como Ingeniero de Células Senior y Bioquímico. El Dr. Kawamura aporta una amplia experiencia en bioquímica, biología molecular y biología celular. Tiene un historial comprobado en el desarrollo de nuevos métodos para la creación de modelos celulares, expresión de proteínas y producción de ADN/ARN. Notablemente, el Dr. Kawamura ha autorizado patentes en tecnología de edición genética, incluida la tecnología ABBIE de SOHM.
Se espera que el nombramiento del Dr. Kawamura mejore las capacidades científicas de SOHM y apoye el avance y la comercialización de su tecnología de edición genética ABBIE. La compañía anticipa que su experiencia ayudará en el lanzamiento oportuno de los kits ABBIE, como se anunció anteriormente para el trimestre actual.
SOHM, Inc. (OTC PINK:SHMN)는 제약 및 생명공학 회사로, Dr. Tetsuya Kawamura, Ph.D.를 선임 세포 엔지니어 및 생화학자로 임명했다고 발표했습니다. Kawamura 박사는 생화학, 분자 생물학 및 세포 생물학 분야에서 폭넓은 경험을 보유하고 있습니다. 그는 세포 모델 생성, 단백질 발현 및 DNA/RNA 생산을 위한 새로운 방법 개발에서 입증된 성과를 가지고 있습니다. 특히, Kawamura 박사는 SOHM의 ABBIE 기술을 포함한 유전자 편집 기술에 대한 특허를 저술하였습니다.
Kawamura 박사의 임명은 SOHM의 과학적 능력을 강화하고 ABBIE 유전자 편집 기술의 발전 및 상용화를 지원할 것으로 기대됩니다. 회사는 그의 전문성이 앞서 발표된 현 분기 내 ABBIE 키트의 적시 출시에 기여할 것이라고 예상하고 있습니다.
SOHM, Inc. (OTC PINK:SHMN), une entreprise pharmaceutique et biotechnologique, a annoncé la nomination de Dr. Tetsuya Kawamura, Ph.D. en tant qu'ingénieur cellulaire senior et biochimiste. Le Dr Kawamura possède une vaste expérience en biochimie, biologie moléculaire et biologie cellulaire. Il a un parcours éprouvé dans le développement de nouvelles méthodes pour la création de modèles cellulaires, l'expression de protéines et la production d'ADN/ARN. Notamment, le Dr Kawamura a déposé des brevets dans la technologie d'édition génétique, y compris la technologie ABBIE de SOHM.
La nomination du Dr Kawamura devrait améliorer les capacités scientifiques de SOHM et soutenir l'avancement et la commercialisation de leur technologie d'édition génétique ABBIE. L'entreprise anticipe que son expertise aidera à la sortie dans les délais des kits ABBIE, comme annoncé précédemment pour le trimestre en cours.
SOHM, Inc. (OTC PINK:SHMN), ein Pharma- und Biotechnologieunternehmen, hat die Ernennung von Dr. Tetsuya Kawamura, Ph.D. zum Senior Cell Engineer und Biochemiker bekannt gegeben. Dr. Kawamura bringt umfangreiche Erfahrungen in Biochemie, Molekularbiologie und Zellbiologie mit. Er hat eine nachweisliche Erfolgsbilanz in der Entwicklung neuer Methoden zur Erstellung von Zellmodellen, Proteinausdruck und DNA/RNA-Produktion. Bemerkenswert ist, dass Dr. Kawamura Patente in der Technologie des Gen-Editings verfasst hat, einschließlich der ABBIE-Technologie von SOHM.
Die Ernennung von Dr. Kawamura wird voraussichtlich die wissenschaftlichen Fähigkeiten von SOHM verbessern und die Weiterentwicklung und Kommerzialisierung ihrer ABBIE-Gentechnologie unterstützen. Das Unternehmen erwartet, dass seine Expertise zur fristgerechten Einführung der ABBIE-Kits beiträgt, wie zuvor für das laufende Quartal angekündigt.
- Appointment of Dr. Tetsuya Kawamura, a highly qualified expert in biochemistry and cellular biology
- Dr. Kawamura has authored patents in gene editing technology, including SOHM's ABBIE technology
- Expected to enhance SOHM's scientific capabilities and support ABBIE gene editing technology commercialization
- Anticipated to aid in the timely release of ABBIE kits in the current quarter
- None.
CHINO HILLS, CA / ACCESSWIRE / August 2, 2024 / SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnology company that manufactures and markets generic drugs covering numerous treatment categories, announced today the appointment of Dr. Tetsuya Kawamura, Ph.D., as a Cell Engineer and Biochemist.
Baron Night, CEO shared that, we are excited to announce the addition of Dr. Tetsuya Kawamura, Ph.D., to our team as a Senior Cell Engineer and Biochemist. Dr. Kawamura brings a wealth of experience and expertise in the fields of biochemistry, molecular biology, and cellular biology, further enhancing SOHM's commitment to scientific excellence and innovation.
Dr. Kawamura is a distinguished life science professional with extensive experience in biochemistry, molecular, and cellular biology. He has a proven track record of developing new methods and utilizing various instruments for analytical characterization relevant to cell model creation, protein expression and purification, and DNA/RNA production. His productivity, problem-solving skills, and broad knowledge base make him a valuable asset to SOHM. Moreover, Dr. Kawamura has authored patents in gene editing technology, including our own ABBIE technology. Dr. Kawamura has an extensive peer reviewed publication track record and will also support grant writing initiatives. Mr. Night added.
Dr. Kawamura holds a Ph.D. in Chemistry from the University of California, Santa Barbara, an M.S. in Chemistry from the University of Oregon, Eugene, and a B.S. in Music and Biochemistry from California Polytechnic State University, San Luis Obispo.
Dr. Kawamura's diverse academic background and professional experience with genome editing, molecular biology, and biochemistry will be instrumental in our advancement and commercialization of ABBIE gene editing technology. His entry greatly aids our timely release of ABBIE kits as we announced earlier in the current quarter.
For more information about SOHM Inc. and its work on ABBIE, please visit www.SOHM.com
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy.
To learn more about SOHM, Inc., visit www.SOHM.com.
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on accesswire.com
FAQ
Who is Dr. Tetsuya Kawamura and what role has he taken at SOHM, Inc. (SHMN)?
What is Dr. Kawamura's contribution to SOHM's (SHMN) gene editing technology?
How will Dr. Kawamura's appointment impact SOHM's (SHMN) product development?
What is SOHM, Inc. (SHMN) and what does it specialize in?
